Interferon alpha-2b controlled-release - Avadel Pharmaceuticals
Alternative Names: IFN alfa-2b XL; IFN alpha-2b XL; IFN-α XL; Interferon alfa-2b XL; Interferon alpha-2b XL; Interferon alpha-2b XL - Avadel Pharmaceuticals; Long-acting IFN-α XL; Long-acting interferon alpha-2bLatest Information Update: 02 Oct 2021
At a glance
- Originator Flamel Technologies
- Class Antineoplastics; Antivirals; Interferons; Recombinant proteins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 23 Oct 2012 Interferon alpha-2b controlled-release - Flamel Technologies is available for licensing \http://www.flamel.com/\
- 18 Oct 2011 Interferon alpha-2b (controlled-release) is still in phase IIa trials for Hepatitis C in France
- 19 Dec 2009 Phase-IIa clinical trials in Hepatitis C in France (SC)